MARINA DEL REY, Calif.--(BUSINESS WIRE)--Strategic healthcare communications firm Nobles Global Communications has been selected as the agency of record for Calhoun Vision, developer of a revolutionary ocular technology designed to allow cataract surgeons to adjust the power of a lens after it has been implanted in the eye.
"We were looking for an agency that not only understood the complexity and challenges of communicating our progress on bringing advanced vision technology to the world, but who were also a trusted partner that is as committed to our success as we are,” said D. Verne Sharma, chairman and chief executive officer of Calhoun Vision. “We found exactly what we wanted in Nobles Global Communications.”
Nobles Global Communications will be responsible for strategic public relations and initiatives designed to raise the visibility of the company with potential investors, increase understanding of the underlying technology, and help drive clinical trial enrollment in the Phase III clinical study of its Light Adjustable Lens (LAL®). The firm will also work with its international partners on the upcoming launch of the next generation LAL in Europe, where it received CE Mark approval in 2007.
“Calhoun Vision is revolutionizing the way cataract and lens implant surgery is performed, and we look forward to helping the company tell its story as it conducts U.S. clinical trials of the Light Adjustable Lens and looks ahead to making the technology available to U.S. surgeons and their patients,” said Laura Nobles, founder and CEO of Nobles Global Communications. “We believe Calhoun Vision is the perfect fit for our firm’s model, which is dedicated to providing only senior-level support for healthcare innovators that are not just advancing the industry, but completely rewriting how we think about care today and well into the future.”
About Calhoun Vision
Calhoun Vision is redefining lens implant surgery by developing technology that enables surgeons to change the power of a lens after it has been implanted, for the purpose of providing unparalleled visual outcomes. The company develops intraocular lenses that, when combined with a custom-designed digital light source, are intended to enable the surgeon to modify intraocular lens power after implantation to the specific, individual visual needs of each patient. Calhoun Vision’s Light Adjustable Lens (LAL®) is CE Mark approved for use in Europe, and is commercially available to patients in Germany, the United Kingdom, France, Italy, Spain, Mexico and the Czech Republic. It is currently in the third phase of clinical trials before submission for marketing approval in the United States.
About Nobles Global Communications
Founded in 2006 in Los Angeles, Nobles Global Communications is a strategic public relations and marketing services firm dedicated to serving health care innovators from around the world. The organization provides exclusively senior-level guidance and support for companies across the health care continuum. For more information, please visit www.noblesgc.com.
Caution: In the United States, the Light Adjustable Lens (LAL) is an investigational device and is not approved or cleared for sale within the United States. Limited by Federal (or United States) law to investigational use.